RDUS

Radius Health, Inc. NASDAQ Global Market
$10.3
Open: $10.101 High: $10.345 Low: $10.1 Close: $10.125
Range: 2022-06-27 - 2022-06-28
Volume:575,345
Market: Open
RDUS
Radius Health, Inc. ATTN: PRINCIPAL FINANCE OFFICER https://www.radiuspharm.com
Radius Health Inc is an integrated biopharmaceutical company. It develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company's product, TYMLOS, is for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. The product pipeline of the company includes Abaloparatide-patch for the treatment of postmenopausal women with osteoporosis, Elacestrant, and RAD140. It primarily operates the business in the United States of America and generates key revenue from the sales of TYMLOS.
  • CEO: Jesper Hoiland
  • Employees: 293
  • Sector: Healthcare
  • Industry: Drug Manufacturers
Latest Stocks Posts
Card image
Card image
Card image
RDUS News
Latest news about the RDUS